A dual B cell cytokine antagonist of BAFF and APRIL with best-in-class potential

ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases. Engineered by directed evolution, ALPN-303 potently inhibits the pleiotropic B cell cytokines B cell activating factor (BAFF, BLyS) and a proliferation inducing ligand (APRIL), which play key roles in B cell development, differentiation, and survival, and together contribute to the pathogenesis of B cell-related autoimmune diseases like systemic lupus erythematosus (SLE), Sjögren’s syndrome, inflammatory arthritis, multiple sclerosis, and many others. By simultaneously blocking these two cytokines, ALPN-303 has the potential to improve outcomes in patients suffering from severe autoimmune and/or inflammatory diseases.

ALPN-303: An Engineered Inhibitor of BAFF and APRIL for B Cell Mediated Inflammatory Diseases

ALPN-303 Appears Superior to Existing BAFF/APRIL Inhibitors in vitro

ALPN-303 Exhibits Encouraging Preclinical Efficacy in Connective Tissue Disease

The best-in-class potential of ALPN-303 is supported by research presented at the 2020 EULAR Virtual Congress demonstrating TACI vTDs:

  • Appears more potent than existing BAFF and APRIL inhibitors in vitro and in vivo
  • In models of lupus and Sjögren’s syndrome, reduce key markers of renal disease and sialoadenitis relative to controls

Details of our published research can be found here.